June 23, 2021 | Deals

GCA Altium advises EMERAM Capital Partners on the sale of MEONA to Trill Impact

GCA Altium acted as exclusive financial advisor to EMERAM Capital Partners and the management of MEONA on the sale of the healthcare IT powerhouse to Trill Impact, a Sweden-based private equity investor focusing on impact investing.

MEONA, an innovation leader in clinical software, was founded in 2008 by PD Dr. Tobias Schäfer and Dr. Matthias Wuttke in Freiburg, Germany. Together with doctors, nurses, pharmacists and other experts from the healthcare sector, they developed the MEONA software, which meets the requirements of modern everyday hospital life. MEONA makes an important contribution to improving quality in healthcare; the software increases safety and time for patients, and also ensures smooth, completely digital processes without media disruptions and thereby enables cost-efficient treatments.

The current group was formed in 2017 under the leadership of EMERAM as a combination of Meona GmbH and E .care bvba, and was expanded in 2019 with the acquisition of Dr. Heni Software GmbH & Co. KG. Since then, MEONA has continuously extended its product portfolio through its own developments and has successfully driven its internationalisation. Due to the strong growth of the company over the past few years, the number of employees has doubled to more than 140.

Ownership of MEONA will now be passed on from funds advised by EMERAM Capital Partners, one of the leading investment firms for medium-sized companies in the German-speaking region, to the Sweden-based impact investor Trill Impact.

Kai Köppen, Senior Partner at EMERAM Capital Partners, commented: “Together we have developed MEONA over the past years. Today, the company is a leading provider of software solutions for hospitals. As business development partner, EMERAM has supported MEONA in its strategic positioning and the continuous development of the organisation. We have now found an ideal partner for the next growth phase of the company, as Trill Impact is also acquiring i-SOLUTIONS Health GmbH, with whom MEONA has already been in contact for some time. Subject to the relevant antitrust approvals, this will create another strong player in the healthcare IT market. We welcome this step and support it accordingly with our sale.”

PD Dr. Tobias Schäfer, CEO of MEONA, added: “MEONA has benefited substantially from EMERAM’s support which has enabled us to make the best possible use of the market opportunities arising from the ongoing digitalisation in healthcare and to expand our market position. Together with EMERAM, we have developed MEONA from a specialist in patient charting and medication software to a leading clinical workspace provider. We are well positioned to benefit from the opportunities offered by the Hospital Future Act (KHZG), which has come into force in October 2020, and for which we offer numerous solutions that will further accelerate MEONA’s growth. Together with our new owner, we want to continue our successful course.”

Previous Next